Athersys Company

Athersys focuses on an adult-derived "off-the-shelf" therapy under development for several neurological and cardiovascular diseases, as well as inflammatory, immune and related disorders. Developed from Multipotent Adult Progenitor Cells (MAPC®) obtained from the bone marrow of healthy, consenting adult donors.

Athersys Founder, Chairman, and CEO Gil Van Bokkelen, PhD, told Ed Henry on his Fox News Channel program “America’s Newsroom” April 1 that the company was in active talks with the FDA about the design and implementation of a Phase III study of MultiStem “that will involve several hundred patients, that will be focused specifically on COVID-19 patients that are experiencing [ARDS].”
Technology: COVID
Industry: Treatments
Headquarters: United States
Founded Date: N/A
Employees Number: N/A
Funding Status: N/A

Visit Website
Register and Claim Ownership